Analyst Price Targets — CGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 21, 2026 10:07 am | — | Leerink Partners | $5.00 | $2.71 | TheFly | Compugen price target lowered to $5 from $13 at Leerink |
| January 7, 2026 11:08 am | — | H.C. Wainwright | $4.00 | $1.55 | TheFly | Compugen initiated with a Buy at H.C. Wainwright |
| May 21, 2024 7:48 am | Asthika Goonewardene | Truist Financial | $4.00 | $1.74 | TheFly | Compugen price target lowered to $4 from $5 at Truist |
| May 20, 2024 3:43 pm | Stephen Willey | Stifel Nicolaus | $4.00 | $1.74 | StreetInsider | Stifel Reiterates Buy Rating on Compugen (CGEN) |
| May 20, 2024 1:21 pm | Asthika Goonewardene | Truist Financial | $5.00 | $1.74 | StreetInsider | Compugen (CGEN) PT Raised to $5 at Truist Securities |
Latest News for CGEN
HOLON, Israel, June 18, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, in Copenhagen,…
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
HOLON, Israel, June 11, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress…
HOLON, Israel, June 8, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will participate in Jones Trading's Mapping the Path from Target to Patient: Fireside Chat Series with Leaders in AI/ ML-based Drug Development on Monday, June 15, 2026, from 10:30-11:00 AM…
Compugen (CGEN) is maintained at a "Buy" rating, driven by advancing clinical programs and upcoming catalysts in oncology. Rilvegostomig, partnered with AstraZeneca, is being evaluated in 11 phase 3 studies, with strong phase 1b/2 data in HER2+ gastric cancer [70% cORR]. New data from DESTINY-Gastric03 will be presented at ASCO 2026, and interim analysis for COM701 in ovarian cancer is expected Q1 2027.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CGEN.
U.S. House Trading
No House trades found for CGEN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.